<DOC>
	<DOCNO>NCT01676675</DOCNO>
	<brief_summary>Influenza acute respiratory infection cause influenza virus high incidence serious complication even cause death . According announcement release World Health Organization ( WHO ) , number global annual influenza case 0.6 1.2 billion 0.5 1 million people die . The emergence new subtype influenza virus may cause influenza pandemic occurence every 10 50 year cause serious adverse consequence human health social welfare worldwide . From 1997 2003，the H5N1 virus infection increase highly gradually spread Europe , Africa country region . High mortality cause H5N1 virus attract WHO national government great attention . So meaningful develop vaccine provide effective antibody reduce number infection . The objective study evaluate safety preliminary immunogenicity whole virus inactivate influenza H5N1 vaccine .</brief_summary>
	<brief_title>A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine Healthy Adolescents Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subject age 12 60 year old normal intelligence ; The subject ' guardian able understand sign inform consent ; Subjects establish healthy medical history questioning , physical examination clinical decision ; Subjects comply requirement clinical trial protocol ; Subjects never receive influenza H5N1 vaccine preventive product ; Subjects temperature ≤37°C axillary setting . Exclusion Criteria first dose : Women pregnancy / lactation plan pregnant study ; The subject history allergy allergic Ingredient vaccine , egg , ovalbumin ; Had serious adverse reaction previous vaccination , allergy , hive , difficult breath , angioneurotic edema abdominal pain ; Autoimmune diseases immune deficiency ; Had asthma , past two year , condition unstable need emergency treatment , hospitalization oral intravenous corticosteroid ; Diabete ( type I type II ) include gestational diabete ; Thyroidectomy history , treatment thyroid diseases past 12 month ; Over past 3 year , severe angioneurotic edema , need treatment past 2 year ; Severe hypertension blood pressure still 150/100 mmHg drug maintenance therapy ; coagulation abnormality diagnose doctor ( lack coagulation factor , coagulation disorder disease , platelet abnormality ) coagulation disorder ; Malignancy , active treat tumor without explicitly cure , possibility recurrence study period ; Epilepsy include alcohol epilepsy stop drinking first 3 year simplicity require treatment past 3 year ; Asplenia , functional asplenia , circumstance lead asplenia splenectomy ; GuillainBarre syndrome ; Had immunosuppressive therapy , cytotoxic therapy , inhaled corticosteroid ( exclude corticosteroid spray treat allergic rhinitis corticosteroid treatment acute uncomplicated dermatitis ) within past six month ; Received immune globulin three month study ; Received experimental drug 30 day study ; Received live attenuate vaccine 30 day study ; Receiving subunit inactivate vaccine 14days study , pneumococcal vaccine allergy treatment ; In prevention treatment antiTB ( antituberculosis ) ; Had fever ( axillary temperature ≥ 38.0℃ ) 3 day vaccination acute illness past five day require systemic antibiotic antiviral therapy ) ; The subject unable comply study requirement psychology , mental illness dualstage affective psychosis well control within past two year psychology medication suicidal tendency past five year ; According researcher , contrary study protocol effect sign informed consent due variety medical , psychological , social condition , occupational factor condition . Exclusion Criteria second dose : Had vaccinationrelated Grade 3 adverse reaction 72 hour first vaccination ; Any situation meet exclusion criterion state exclusion criterion first dose ; Had serious adverse reaction cause study vaccination . Acute infection ; Any condition investigator believe may affect evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>whole virus</keyword>
	<keyword>inactivate</keyword>
	<keyword>influenza</keyword>
	<keyword>H5N1 vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
</DOC>